A61K38/1767

Targeting M2-like tumor-associated macrophages by using melittin-based proapoptotic peptide

The present invention relates to a melittin-anticancer drug conjugate in which melittin and an anticancer drug are conjugated, and to a method of preparing a melittin-anticancer drug conjugate by connecting melittin and an anticancer drug. A conjugate of the present invention is an anticancer material for targeting M2-type tumor-associated macrophages (TAM) and exhibits an excellent effect of selectively selecting M2-type tumor-associated macrophages (TAM), and thus may be used for a use of drug delivery for targeting M2-type tumor-associated macrophages.

Apoaequorin and Curcumin Containing Compositions and Methods
20230078821 · 2023-03-16 ·

Compositions containing apoaequorin and curcumin and methods for their use in treating symptoms and disorders, for example, mental disorder, anxiety, cognitive function, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.

COMPOSITION CONTAINING PEPTIDE OR PEPTIDE COMPOUND AS ACTIVE INGREDIENT, AND MEDICAL USE THEREFOR

The present invention relates to a composition for preventing or treating an inflammatory disease induced by an autoimmune response, the composition comprising a peptide or a peptide mixture as an active ingredient. More specifically, the composition containing, as an active ingredient, peptide P1 to P5 or a mixture thereof may be provided as a treatment agent for an inflammatory disease induced by an autoimmune response, as alleviation of a skin ulcer and skin inflammation in a mouse model with psoriasis was confirmed and an inflammatory symptom in a model with enteritis was alleviated as results of intraperitoneally injecting or applying, as an externally administered agent on the skin, peptide P1 to P5 or the mixture thereof to the mouse animal models with psoriasis and the inflammatory bowel disease, which are inflammatory diseases induced by an autoimmune response.

SYSTEMS, DEVICES, AND METHODS FOR TREATING A PULMONARY DISORDER WITH AN AGENT
20230075851 · 2023-03-09 ·

A medication delivery device for treatment of a pulmonary disorder in a patient includes an elongate member, an expandable member is coupled to a distal end of the elongate member, and an agent delivery portion coupled to an external surface of the expandable member. The agent delivery portion includes an agent that disrupts nerve activity.

Silk-based product formulations and methods of use

Embodiments of the present disclosure include formulations of silk-based product (SBP) formulations and related methods of preparation and use in a variety of applications in the fields of human therapeutics, veterinary medicine, agriculture, and material science.

HYDROPHOBIC SILK FIBROIN COMPOSITIONS AND METHODS OF MAKING THE SAME

The present disclosure relates to compositions, methods of making, and methods of using a modified silk-based composition having a selectively tunable hydrophobicity. The provided compositions include silk fibroin having a haloalkyl substituent. The haloalkyl substituent is coupled to an amino acid of the silk fibroin though a linking agent.

DIETARY SUPPLEMENT TO PROMOTE GUT HEALTH
20220323390 · 2022-10-13 ·

Provided are dietary supplement composition comprising one or both of L-theanine and a trace mineral complex, optionally in combination with bioactive peptides, in an amount or amounts individually or in combination effective to promote gut health. Further optional components include a fiber oligosaccharide prebiotic, a polyphenol prebiotic, and a polynucleotide or blend. Examples of benefits include one or more of: —an increase in the amount of total short-chain fatty acid production or of at least one of propionate, acetate and butyrate; —an increase the expression or level of at least one tight junction protein (for example, claudin-1, claudin-3, claudin-4, occludin, or a zona occludens protein) or mucin-3 or decrease the expression or level of claudin-2; —an increase in transepithelial electrical resistance; —an increase in the abundance or diversity of a member or phylum of the intestinal bacterial community of the Intestinal lumen or mucus area (for example, Firmicutes, Bacteroidetes, Lactobacilli, Bifidobacteria, F. prausnitzii, or A. muciniphila); —an increase in the expression or level of at least one intestinal surface area marker protein (for example, villin, myosin, cadherin or sucrase-isomaltase). Methods for using such supplements are also disclosed.

SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY
20220323369 · 2022-10-13 ·

Disclosed are (i) compounds of formula I, or pharmaceutically acceptable salts thereof; and (ii) lipidoid nanoparticles comprising compound of formula I or pharmaceutically acceptable salts thereof, as well as their use as vehicles for drug delivery across the blood-brain barrier.

METHODS AND COMPOSITIONS WITH PURIFIED BOMBYX MORI COCOON SILK PEPTIDE FIBER AND REFINED BUGLOSSOIDES ARVENSIS SEED OIL PROVIDING ANTI-INFLAMMATORY EFFECTS AND NEUROPROTECTION FOR DISEASE STATES

The present invention is directed to compositions comprising purified Bombyx mori cocoon silk peptide fiber, refined Buglossoides arvensis seed oil, and optionally Blueberry extract, and related methods for decreasing inflammation and providing neuroprotection. The compositions provide synergistic effects and may be used to treat relevant diseases and disorders.

METHODS OF MAKING STABLE SILK FIBROIN FORMULATIONS
20220331400 · 2022-10-20 ·

The present disclosure includes formulations of processed silk and related methods of preparation and use in a variety of applications.